Coronary thrombolysis: pharmacological considerations with emphasis on tissue-type plasminogen activator (t-PA).
D000818:Animals; D003327:Coronary Disease / Q000188:drug therapy*; D005341:Fibrinolysin / Q000037:antagonists & inhibitors / Q000502:physiology; D005342:Fibrinolysis / Q000187:drug effects*; D006801:Humans; D010958:Plasminogen / Q000502:physiology; D010960:Plasminogen Activators / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D013300:Streptokinase / Q000494:pharmacology; D014568:Urokinase-Type Plasminogen Activator / Q000494:pharmacology
D010958:Plasminogen; D013300:Streptokinase; D010960:Plasminogen Activators; D005341:Fibrinolysin; D014568:Urokinase-Type Plasminogen Activator